Newer approaches for relapsed/refractory myeloma patients with Dr. Ravi Vij, MD, Washington University School of Medicine

Newer approaches for relapsed/refractory myeloma patients with Dr. Ravi Vij, MD, Washington University School of Medicine
Event Description
Dr. Ravi Vij, MD Washington University School of Medicine Interview Date: January 29, 2015
Dr. Ravi Vij, MD, discusses newer options for relapsed/refractory myeloma patients. He shares that little is known about why some patients become drug resistant and says that drug resistance can't be predicted. He notes the complexities of myeloma, that there isn't a single clone of the disease in each patient, but rather sub-clones where one could be affected by treatment and other resistant to treatment. He shares the use of the new monoclonal antibodies elotuzumab and the two new anti-CD38 monoclonal antibodies. He also shares that the newer drugs carfilzomib and pomalidomide are helping relapsed patients and may give better response rates. He mentions several other new inhibitors that may also be effective for relapsed patients including ARRY-520, KPT-330 and Ibrutinib. These are still in the early stages of study, but represent a growing number of newer options being tested. He notes that the field is maturing, with new genetic testing able to identify specific genes that are mutated in myeloma and other cancers. He describes the difference between the gene expression profile (GEP) and whole genome sequencing and tells us that the $1000 genome test is here today, but says the challenge is finding the people and systems to interpret that data. He describes "personalized medicine" and "precision medicine" and suggests that these new ways of looking at myeloma and cancer in general may require a different approach to clinical trials. The Myeloma Crowd Radio Show with Dr. Vij
Schedule & Agenda
Speakers & Moderators

Ravi Vij, MD, MBA, is Professor of Medicine at the Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. Dr. Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He has research interests in multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij serves on numerous committees including the International Myeloma Working Group (IWMG), the Core Transplant Myeloma and Leukemia Committees of the CALGB, the Steering Committee of the Multiple Myeloma Research Consortium, and the Myeloma Committee of the BMT Clinical Trials Network (CTN). His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). He has authored more than 130 publications in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. He has authored the book Contemporary Management of Multiple Myeloma and several chapters in books, including Multiple Myeloma and Plasma Cell Dyscrasias in the Washington Manual of Oncology. He has served as a review for journals including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology and Haematologica.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org






Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.